Albumin's Role in Paclitaxel Delivery
Albumin binds paclitaxel, a hydrophobic chemotherapy drug, forming a stable complex that enhances its solubility in blood plasma. This binding occurs primarily at albumin's Sudlow sites I and II, with high affinity (association constant ~10^6 M^{-1}), allowing paclitaxel to circulate without rapid clearance.[1]
How Albumin Boosts Membrane Penetration
Paclitaxel-albumin complexes (like in Abraxane) promote transcytosis across endothelial barriers, such as the blood-brain barrier (BBB) or tumor vasculature. Albumin receptors gp60 and SPARC on endothelial and tumor cells trigger caveolin-mediated endocytosis. The complex enters cells via receptor binding, releases paclitaxel intracellularly, and increases penetration 2-5 fold compared to Cremophor-el paclitaxel in vitro and in tumor models.[2][3]
Evidence from Abraxane Formulation
Abraxane, nanoparticle albumin-bound paclitaxel (nab-paclitaxel), demonstrates superior membrane permeability in preclinical studies. It crosses tumor endothelia faster due to albumin's tumor accumulation via enhanced permeability and retention (EPR) effect, leading to higher intratumoral drug levels (up to 33% more than solvent-based paclitaxel).[4]
Comparison to Cremophor Paclitaxel
Cremophor micelles hinder membrane penetration by trapping paclitaxel and causing endothelial toxicity, reducing uptake. Albumin avoids this, improving diffusion across lipid bilayers and reducing efflux via P-glycoprotein pumps.[2]
Clinical and Tumor-Specific Effects
In patients, albumin-paclitaxel shows better tumor penetration in breast, lung, and pancreatic cancers, correlating with gp60/SPARC expression. However, low albumin levels (<3.5 g/dL) may reduce efficacy by limiting complex formation.[5]
Sources
[1] DrugPatentWatch.com - Paclitaxel patents and formulations
[2] Desai et al., Clin Cancer Res (2006); DOI: 10.1158/1078-0432.CCR-04-1631
[3] Kratz et al., Expert Opin Drug Deliv (2007); DOI: 10.1517/17425247.4.4.489
[4] Sparano et al., J Clin Oncol (2015); DOI: 10.1200/JCO.2014.57.6620
[5] von Hoff et al., J Clin Oncol (2011); DOI: 10.1200/JCO.2010.33.7876